Anaplastic Lymphoma Kinase Inhibitors Market
1 Study Coverage
1.1 Anaplastic Lymphoma Kinase Inhibitors Product Introduction
1.2 Market by Type
1.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib Hydrochloride
1.3 Market by Application
1.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 NSCLC
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Neuroblastoma
1.3.6 Ovarian Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Estimates and Forecasts 2017-2028
2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Estimates and Forecasts 2017-2028
2.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region
2.4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2017-2022)
2.4.2 Global Sales Anaplastic Lymphoma Kinase Inhibitors by Region (2023-2028)
2.5 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region
2.5.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2017-2022)
2.5.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Manufacturers
3.1.1 Global Top Anaplastic Lymphoma Kinase Inhibitors Manufacturers by Sales (2017-2022)
3.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anaplastic Lymphoma Kinase Inhibitors in 2021
3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturers
3.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturers (2017-2022)
3.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Anaplastic Lymphoma Kinase Inhibitors Revenue in 2021
3.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Anaplastic Lymphoma Kinase Inhibitors Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type
4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Historical Sales by Type (2017-2022)
4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Sales by Type (2023-2028)
4.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
4.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type
4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Historical Revenue by Type (2017-2022)
4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Revenue by Type (2023-2028)
4.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
4.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type
4.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2017-2022)
4.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application
5.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Historical Sales by Application (2017-2022)
5.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Sales by Application (2023-2028)
5.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
5.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application
5.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Historical Revenue by Application (2017-2022)
5.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Revenue by Application (2023-2028)
5.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
5.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Application
5.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2017-2022)
5.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Application (2023-2028)
6 North America
6.1 North America Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
6.1.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028)
6.1.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2028)
6.2 North America Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
6.2.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028)
6.2.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2028)
6.3 North America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
6.3.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2028)
6.3.2 North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
7.1.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028)
7.1.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2028)
7.2 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
7.2.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028)
7.2.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2028)
7.3 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
7.3.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2028)
7.3.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
8.1.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028)
8.1.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2028)
8.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
8.2.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028)
8.2.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2028)
8.3 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size by Region
8.3.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2017-2028)
8.3.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
9.1.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028)
9.1.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2028)
9.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
9.2.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028)
9.2.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2028)
9.3 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
9.3.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2028)
9.3.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
10.1.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028)
10.1.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2028)
10.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
10.2.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028)
10.2.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2028)
10.3 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Size by Country
10.3.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2028)
10.3.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Betta Pharmaceutcials Co., Ltd.
11.1.1 Betta Pharmaceutcials Co., Ltd. Corporation Information
11.1.2 Betta Pharmaceutcials Co., Ltd. Overview
11.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Betta Pharmaceutcials Co., Ltd. Recent Developments
11.2 Crtierium, Inc.
11.2.1 Crtierium, Inc. Corporation Information
11.2.2 Crtierium, Inc. Overview
11.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Crtierium, Inc. Recent Developments
11.3 F.Hoffman-La Roche Ltd.
11.3.1 F.Hoffman-La Roche Ltd. Corporation Information
11.3.2 F.Hoffman-La Roche Ltd. Overview
11.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 F.Hoffman-La Roche Ltd. Recent Developments
11.4 Helsinn Therapeutics
11.4.1 Helsinn Therapeutics Corporation Information
11.4.2 Helsinn Therapeutics Overview
11.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Helsinn Therapeutics Recent Developments
11.5 Novartis AG.
11.5.1 Novartis AG. Corporation Information
11.5.2 Novartis AG. Overview
11.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis AG. Recent Developments
11.6 Oncoethix GmbH
11.6.1 Oncoethix GmbH Corporation Information
11.6.2 Oncoethix GmbH Overview
11.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Oncoethix GmbH Recent Developments
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Corporation Information
11.7.2 Pfizer, Inc. Overview
11.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer, Inc. Recent Developments
11.8 Takeda Pharmaceutical Co., Ltd.
11.8.1 Takeda Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Takeda Pharmaceutical Co., Ltd. Overview
11.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Takeda Pharmaceutical Co., Ltd. Recent Developments
11.9 Xcovery Holding Company, LLC
11.9.1 Xcovery Holding Company, LLC Corporation Information
11.9.2 Xcovery Holding Company, LLC Overview
11.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Xcovery Holding Company, LLC Recent Developments
11.10 Tesaro, Inc.
11.10.1 Tesaro, Inc. Corporation Information
11.10.2 Tesaro, Inc. Overview
11.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Tesaro, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anaplastic Lymphoma Kinase Inhibitors Industry Chain Analysis
12.2 Anaplastic Lymphoma Kinase Inhibitors Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anaplastic Lymphoma Kinase Inhibitors Production Mode & Process
12.4 Anaplastic Lymphoma Kinase Inhibitors Sales and Marketing
12.4.1 Anaplastic Lymphoma Kinase Inhibitors Sales Channels
12.4.2 Anaplastic Lymphoma Kinase Inhibitors Distributors
12.5 Anaplastic Lymphoma Kinase Inhibitors Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Anaplastic Lymphoma Kinase Inhibitors Industry Trends
13.2 Anaplastic Lymphoma Kinase Inhibitors Market Drivers
13.3 Anaplastic Lymphoma Kinase Inhibitors Market Challenges
13.4 Anaplastic Lymphoma Kinase Inhibitors Market Restraints
14 Key Findings in The Global Anaplastic Lymphoma Kinase Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Crizotinib
Table 3. Major Manufacturers of Ceritinib
Table 4. Major Manufacturers of Alectinib Hydrochloride
Table 5. Global Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2017-2022) & (MT)
Table 8. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2017-2022)
Table 9. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2023-2028) & (MT)
Table 10. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2023-2028)
Table 11. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2017-2022)
Table 13. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2023-2028)
Table 15. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Manufacturers (2017-2022) & (MT)
Table 16. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Manufacturers (2017-2022)
Table 17. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Manufacturers (2017-2022)
Table 19. Anaplastic Lymphoma Kinase Inhibitors Price by Manufacturers (2017-2022) &(USD/MT)
Table 20. Global Anaplastic Lymphoma Kinase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Anaplastic Lymphoma Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2021)
Table 22. Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Offered
Table 24. Date of Manufacturers Enter into Anaplastic Lymphoma Kinase Inhibitors Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 27. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 28. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Type (2017-2022)
Table 29. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Type (2023-2028)
Table 30. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Type (2017-2022)
Table 33. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Type (2023-2028)
Table 34. Anaplastic Lymphoma Kinase Inhibitors Price by Type (2017-2022) & (USD/MT)
Table 35. Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Type (2023-2028) & (USD/MT)
Table 36. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 37. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 38. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Application (2017-2022)
Table 39. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Application (2023-2028)
Table 40. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Application (2017-2022)
Table 43. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Application (2023-2028)
Table 44. Anaplastic Lymphoma Kinase Inhibitors Price by Application (2017-2022) & (USD/MT)
Table 45. Global Anaplastic Lymphoma Kinase Inhibitors Price Forecast by Application (2023-2028) & (USD/MT)
Table 46. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 47. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 48. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 51. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 52. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2022) & (MT)
Table 55. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2023-2028) & (MT)
Table 56. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 59. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 60. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 63. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 64. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2022) & (MT)
Table 67. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2023-2028) & (MT)
Table 68. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 71. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 72. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 75. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 76. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2017-2022) & (MT)
Table 79. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2023-2028) & (MT)
Table 80. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 83. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 84. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 87. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 88. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2022) & (MT)
Table 91. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2023-2028) & (MT)
Table 92. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2022) & (MT)
Table 95. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2023-2028) & (MT)
Table 96. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2022) & (MT)
Table 99. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2023-2028) & (MT)
Table 100. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2017-2022) & (MT)
Table 103. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2023-2028) & (MT)
Table 104. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2023-2028) & (US$ Million)
Table 106. Betta Pharmaceutcials Co., Ltd. Corporation Information
Table 107. Betta Pharmaceutcials Co., Ltd. Description and Major Businesses
Table 108. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 109. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Betta Pharmaceutcials Co., Ltd. Recent Developments
Table 111. Crtierium, Inc. Corporation Information
Table 112. Crtierium, Inc. Description and Major Businesses
Table 113. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 114. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Crtierium, Inc. Recent Developments
Table 116. F.Hoffman-La Roche Ltd. Corporation Information
Table 117. F.Hoffman-La Roche Ltd. Description and Major Businesses
Table 118. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 119. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. F.Hoffman-La Roche Ltd. Recent Developments
Table 121. Helsinn Therapeutics Corporation Information
Table 122. Helsinn Therapeutics Description and Major Businesses
Table 123. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 124. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Helsinn Therapeutics Recent Developments
Table 126. Novartis AG. Corporation Information
Table 127. Novartis AG. Description and Major Businesses
Table 128. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 129. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Novartis AG. Recent Developments
Table 131. Oncoethix GmbH Corporation Information
Table 132. Oncoethix GmbH Description and Major Businesses
Table 133. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 134. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Oncoethix GmbH Recent Developments
Table 136. Pfizer, Inc. Corporation Information
Table 137. Pfizer, Inc. Description and Major Businesses
Table 138. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 139. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Pfizer, Inc. Recent Developments
Table 141. Takeda Pharmaceutical Co., Ltd. Corporation Information
Table 142. Takeda Pharmaceutical Co., Ltd. Description and Major Businesses
Table 143. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 144. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Takeda Pharmaceutical Co., Ltd. Recent Developments
Table 146. Xcovery Holding Company, LLC Corporation Information
Table 147. Xcovery Holding Company, LLC Description and Major Businesses
Table 148. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 149. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Xcovery Holding Company, LLC Recent Developments
Table 151. Tesaro, Inc. Corporation Information
Table 152. Tesaro, Inc. Description and Major Businesses
Table 153. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 154. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Tesaro, Inc. Recent Developments
Table 156. Key Raw Materials Lists
Table 157. Raw Materials Key Suppliers Lists
Table 158. Anaplastic Lymphoma Kinase Inhibitors Distributors List
Table 159. Anaplastic Lymphoma Kinase Inhibitors Customers List
Table 160. Anaplastic Lymphoma Kinase Inhibitors Market Trends
Table 161. Anaplastic Lymphoma Kinase Inhibitors Market Drivers
Table 162. Anaplastic Lymphoma Kinase Inhibitors Market Challenges
Table 163. Anaplastic Lymphoma Kinase Inhibitors Market Restraints
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Anaplastic Lymphoma Kinase Inhibitors Product Picture
Figure 3. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Type in 2021 & 2028
Figure 3. Crizotinib Product Picture
Figure 4. Ceritinib Product Picture
Figure 5. Alectinib Hydrochloride Product Picture
Figure 6. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Application in 2021 & 2028
Figure 7. NSCLC
Figure 8. Breast Cancer
Figure 9. Colorectal Cancer
Figure 10. Neuroblastoma
Figure 11. Ovarian Cancer
Figure 12. Others
Figure 13. Anaplastic Lymphoma Kinase Inhibitors Report Years Considered
Figure 14. Global Anaplastic Lymphoma Kinase Inhibitors Sales 2017-2028 (MT)
Figure 15. Global Anaplastic Lymphoma Kinase Inhibitors Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Anaplastic Lymphoma Kinase Inhibitors Revenue 2017-2028 (US$ Million)
Figure 17. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2017-2022)
Figure 19. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2023-2028)
Figure 20. North America Anaplastic Lymphoma Kinase Inhibitors Sales YoY (2017-2028) & (MT)
Figure 21. North America Anaplastic Lymphoma Kinase Inhibitors Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Anaplastic Lymphoma Kinase Inhibitors Sales YoY (2017-2028) & (MT)
Figure 23. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales YoY (2017-2028) & (MT)
Figure 25. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales YoY (2017-2028) & (MT)
Figure 27. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales YoY (2017-2028) & (MT)
Figure 29. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Anaplastic Lymphoma Kinase Inhibitors Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Anaplastic Lymphoma Kinase Inhibitors in the World: Market Share by Anaplastic Lymphoma Kinase Inhibitors Revenue in 2021
Figure 32. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 34. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 35. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 36. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 37. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 38. North America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 39. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 40. North America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 41. North America Anaplastic Lymphoma Kinase Inhibitors Sales Share by Country (2017-2028)
Figure 42. North America Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Country (2017-2028)
Figure 43. U.S. Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 46. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 47. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 48. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 49. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Share by Country (2017-2028)
Figure 50. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Country (2017-2028)
Figure 51. Germany Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 52. France Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 59. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 60. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Share by Region (2017-2028)
Figure 61. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Region (2017-2028)
Figure 62. China Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 63. Japan Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 64. South Korea Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 65. India Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 66. Australia Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 67. Taiwan Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 68. Indonesia Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 69. Thailand Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 70. Malaysia Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 71. Philippines Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 72. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 73. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 74. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 75. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 76. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Share by Country (2017-2028)
Figure 77. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Country (2017-2028)
Figure 78. Mexico Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 79. Brazil Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 80. Argentina Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 81. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2017-2028)
Figure 83. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2017-2028)
Figure 85. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Share by Country (2017-2028)
Figure 86. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Country (2017-2028)
Figure 87. Turkey Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 88. Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 89. U.A.E Anaplastic Lymphoma Kinase Inhibitors Revenue (2017-2028) & (US$ Million)
Figure 90. Anaplastic Lymphoma Kinase Inhibitors Value Chain
Figure 91. Anaplastic Lymphoma Kinase Inhibitors Production Process
Figure 92. Channels of Distribution
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Industry Market Size
